Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

References

• Gong X, Chen X, Kuligowski ME, et al. Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase ii and iii studies. Am J Clin Dermatol. 2021;22(4):555–566. doi:10.1007/s40257-021-00610-x
   PubMed Web of Science ®Google Scholar
• Chan LS, Shi VY. Atopic Dermatitis: Inside Out or Outside. 1st ed. Elsevier; 2022.
   Google Scholar
• Smith Begolka W, Chovatiya R, Thibau IJ, Silverberg JI. Financial burden of atopic dermatitis out-of-pocket health care expenses in the United States. Dermatitis. 2020;32(1S):S62–S70. doi:10.1097/DER.0000000000000715
   Web of Science ®Google Scholar
• Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi:10.1111/bjd.19580
   PubMed Web of Science ®Google Scholar
• Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1–11. doi:10.1016/j.jaci.2018.10.032
   PubMed Web of Science ®Google Scholar
• Freitas E, Gooderham M, Torres T. New topical therapies in development for atopic dermatitis. Drugs. 2022;82(8):843–853. doi:10.1007/s40265-022-01722-2
   PubMed Web of Science ®Google Scholar
• Kim BS, Howell MD, Sun K, Papp K, Nasir A, Kuligowski ME. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. 2020;145(2):572–582. doi:10.1016/j.jaci.2019.08.042
   PubMed Web of Science ®Google Scholar
• Chapman S, Gold LS, Lim HW. Janus kinase inhibitors in dermatology: part II. A comprehensive review. J Am Acad Dermatol. 2022;86(2):414–422. doi:10.1016/j.jaad.2021.06.873
   PubMed Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 Phase 3, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863–872. doi:10.1016/j.jaad.2021.04.085
   PubMed Web of Science ®Google Scholar
• Ruxolitinib (Opzelura) for atopic dermatitis. Med Lett Drugs Ther. Available from: https://secure.medicalletter.org/TML-article-1642d. Accessed 21 October 2022.
   Google Scholar
• Bissonnette R, Call RS, Raoof T, et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23(3):355–364. doi:10.1007/s40257-022-00690-3
   PubMed Web of Science ®Google Scholar
• Bashaw ED, Tran DC, Shukla CG, Liu X. Maximal usage trial: an overview of the design of systemic bioavailability trial for topical dermatological products. Ther Innov Regul Sci. 2015;49(1):108–115. doi:10.1177/2168479014539157
   PubMed Web of Science ®Google Scholar
• Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: results from a Phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. 2020;82(6):1305–1313. doi:10.1016/j.jaad.2020.02.009
   PubMed Web of Science ®Google Scholar
• Owens S, Jones H, Kuligowski ME, Howell MD. 18263 Association between an itch-free state in atopic dermatitis treated with ruxolitinib cream and systemic inflammatory mediators. J Am Acad Dermatol. 2020;83(6):AB95–AB95. doi:10.1016/j.jaad.2020.06.469
   Web of Science ®Google Scholar
• Buysse DJ, Lan YU, Moul DE, et al. Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep. 2010;33(6):781–792. doi:10.1093/sleep/33.6.781
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Szepietowski JC, Papp K, et al. 26884 Ruxolitinib cream rapidly decreases pruritus in atopic dermatitis: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB121–AB121. doi:10.1016/j.jaad.2021.06.501
   Web of Science ®Google Scholar
• Simpson EL, Boguniewicz M, Thaçi D, et al. 26887 Effect of ruxolitinib cream on sleep disturbance and sleep impairment: pooled analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB121–AB121. doi:10.1016/j.jaad.2021.06.502
   Web of Science ®Google Scholar
• Eichenfield LF, Simpson EL, Siegfried EC, et al. 27633 Efficacy and safety of ruxolitinib cream among adolescents with atopic dermatitis: pooled Results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB158–AB158. doi:10.1016/j.jaad.2021.06.644
   Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. 27716 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline clinical characteristics: pooled subgroup analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB160–AB161. doi:10.1016/j.jaad.2021.06.653
   Web of Science ®Google Scholar
• Eichenfield LF, Silverberg JI, Kuligowski ME, Venturanza ME, Sun K, Augustin M. 28200 Effects of ruxolitinib cream on work productivity and activity impairment in patients with atopic dermatitis: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB179–AB179. doi:10.1016/j.jaad.2021.06.728
   Web of Science ®Google Scholar
• Simpson EL, Kircik L, Blauvelt A, et al. 24916 Efficacy of ruxolitinib cream in patients with atopic dermatitis who demonstrated partial responses: pooled analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB50–AB50. doi:10.1016/j.jaad.2021.06.226
   Web of Science ®Google Scholar
• Blauvelt A, Eichenfield LF, Kuligowski ME, Venturanza ME, Sun K, Silverberg JI. 27482 Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB148–AB148. doi:10.1016/j.jaad.2021.06.605
   Web of Science ®Google Scholar
• Papp K, Szepietowski JC, Kircik L, et al. 27496 Efficacy of ruxolitinib cream for the treatment of atopic dermatitis by baseline patient demographics: pooled subgroup analysis from two randomized phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB149–AB149. doi:10.1016/j.jaad.2021.06.609
   Web of Science ®Google Scholar
• Simpson EL, Kircik L, Blauvelt A, et al. 27620 Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: pooled results from two phase 3 studies. J Am Acad Dermatol. 2021;85(3):AB157–AB157. doi:10.1016/j.jaad.2021.06.640
   Google Scholar